Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children

详细信息    查看全文

• 作者：Natalia Maximova ; D. Zanon ; F. Rovere ; A. Maestro…
• 关键词：Romiplostim ; Secondary failure of platelet recovery ; Virus infection ; Pediatric patients
• 刊名：International Journal of Hematology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：102
• 期：5
• 页码：626-632
• 全文大小：963 KB
• 参考文献：1.Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365:734–41.CrossRef PubMed
  2.Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO. Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res. 2013;3(3):260–4.PubMedCentral PubMed
  3.Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed
  4.Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer. 2010;54:490–1.CrossRef PubMed
  5.Bat T, Seth M, Steinberg SM, Childs R, Calvo KR, Barrett AJ, et al. Active thrombopoiesis associated with worse severity and activity of chronic graft-versus-host disease. Bone Marrow Transplant. 2013;48(12):1569–73.PubMedCentral CrossRef PubMed
  6.Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112:219–27.CrossRef PubMed
  7.Bruno B, Gooley T, Sullivan KM, Sullivan KM, Davis C, Bensinger WI, Storb R, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:154–62.CrossRef PubMed
  8.Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695–700.CrossRef PubMed
  9.First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood. 1985;65:368–74.PubMed
  10.Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. 2004;33:419–23.CrossRef PubMed
  11.Makar RSL, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12):1041–4.CrossRef PubMed
  12.Buchbinder D, Hsieh L, Krance R, Nugent DJ. Successful treatment of post-transplant thrombocytopenia with romiplostim in a pediatric patient with X-linked chronic granulomatous disease. Pediatr Transplantation. 2014;18(7):E252–4.CrossRef
  13.Calmettes C, Vigouroux S, Tabrizi R, Milpied N. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011;46:1587–9.CrossRef PubMed
  14.Bollag RJ, Sterett M, Reding MT, Key NS, Cohn CS, Ustun C. Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia. Eur J Haematol. 2012;89:361–4.CrossRef PubMed
  15.Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1193–211.PubMedCentral CrossRef PubMed
  16.Harker LA, Carter RA, Marzec UM, Cherry JK, Gunthel CJ, Lennox JL, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy [abstract]. Blood. 1998;92:707a.
  17.Xiao Y, Lin W, Liu Q, Jin R, Fei H. Direct infection of colony forming unit-megakaryocytes by human cytomegalovirus contributes the pathogenesis of idiopathic thrombocytopenic purpura. J Huazhong Univ Sci Technol. 2006;26(5):555–7.CrossRef
  18.First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood. 1985;65(2):368–74.PubMed
  
• 作者单位：Natalia Maximova (1)
  D. Zanon (2)
  F. Rovere (2)
  A. Maestro (2)
  G. Schillani (2)
  R. Paparazzo (2)
  
  1. Bone Marrow Transplantation Unit, Pediatric Hemato Oncology Department, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria 65, 34134, Trieste, Italy
  2. Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Pharmacy and Clinical Pharmacology, Trieste, Italy
  
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘

The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 109/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.